252 related articles for article (PubMed ID: 29671196)
1. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA
J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
[TBL] [Abstract][Full Text] [Related]
3. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
6. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
8. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
10. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N; Proescholdt M; Steinbach JP; Weyerbrock A; Hau P; Grauer O; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Grau S; Hänel M; Schnell O; Krex D; Vajkoczy P; Tabatabai G; Mack F; Schaub C; Tzaridis T; Nießen M; Kebir S; Leutgeb B; Urbach H; Belka C; Stummer W; Glas M; Herrlinger U
Neuro Oncol; 2018 Jun; 20(7):975-985. PubMed ID: 29121274
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
14. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
[TBL] [Abstract][Full Text] [Related]
17. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol.
O'Regan CJ; Kearney H; Beausang A; Farrell MA; Brett FM; Cryan JB; Loftus TE; Buckley PG
J Neurooncol; 2018 Apr; 137(2):233-240. PubMed ID: 29264834
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
20. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.
Urup T; Gillberg L; Kaastrup K; Lü MJS; Michaelsen SR; Andrée Larsen V; Christensen IJ; Broholm H; Lassen U; Grønbaek K; Poulsen HS
Mol Oncol; 2020 May; 14(5):964-973. PubMed ID: 32133779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
